Document is current

Any future updates will be listed below

Author Correction: Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer

Crossref DOI link: https://doi.org/10.1038/s41467-022-33355-0

Published Online: 2022-09-23

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark